Navigation Links
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Date:5/5/2011

EAST HANOVER, N.J., May 5, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4). This marks the first approval of a treatment for this patient population in the US in nearly 30 years(5).

The approval was based on Phase III data from the RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) trial, showing treatment with Afinitor more than doubled the time without tumor growth (median 4.6 to 11.0 months) and reduced the risk of cancer progression by 65% when compared with placebo in patients with advanced pancreatic NET (hazard ratio=0.35 [95% confidence interval (CI), 0.27 to 0.45]; p<0.001). A consistent improvement in progression-free survival was seen with Afinitor in all patient subgroups(1). The FDA determined that the safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumors have not been established(4).

"The FDA approval of Afinitor represents an important step forward for patients with advanced pancreatic NET," said James Yao, MD, Associate Professor of Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. "Patients will now have access to a treatment that has been shown to significantly delay tumor growth and reduce the risk of disease progression."

Approximately 60% of pancreatic NET patients are diagnosed with advanced disease(2). This means that the cancer has already spread to other parts of the body, and is considered aggressive and difficult to treat(3). The five-year survival rate for these patients is 27%(6).

"With this approval, physicians can now offer their patients with progressive pancreatic NET a new treatment helping to fulfill a critical unmet need," said Herve Hoppenot, President
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
2. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
3. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
4. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
5. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
6. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
7. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
8. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
10. Novartis to Expand Global Research Headquarters in Cambridge, MA
11. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
(Date:7/10/2014)... CARLSBAD, Calif. , July 10, 2014 /PRNewswire/ ... products and services, has launched the FreeRunner™ knee ... runners, who suffer from patella mal-tracking return to ... anatomy differently than other braces, providing support when ... move normally when they don,t. Patellofemoral ...
(Date:7/10/2014)... JORDAN, Utah , July 10, 2014  BC ... solutions, and MiE America , Inc., a leading ... have entered into a long-term agreement naming BC Technical ... the US. MiE and BC Technical ... strategic agreement to establish BC Technical as the service ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Inc. today announced that it has been awarded a ... $600,000 from the National Institute of Allergy and Infectious ...  The grant will be used to demonstrate the feasibility ... platelet recovery and improve survival in a mouse model ...
... TOPEX, Inc. announces the sale of its skin cancer ... energy SRT 100 superficial radiotherapy treatment system. Since TOPEX ... operating worldwide at hospital radiation oncology centers, dermatology and ... The low energy superficial radiotherapy system provides patients an ...
Cached Medicine Technology:Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome 2TOPEX Sells Skin Cancer Business Operations to SENSUS Healthcare 2
(Date:7/13/2014)... York (PRWEB) July 13, 2014 The ... http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson & Johnson’s ... bellwether trial, which is expected to get underway next ... in the U.S. District Court, Southern District of West ... be held on August 7, 2014 at 3:00 p.m. ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... Columbus, OH (PRWEB) July 13, 2014 ... by Wright & Schulte LLC to provide consumers with ... can sometimes accompany use of the blood-thinning medication, as ... lawsuits pending in courts around the country. The ... anyone who may have suffered from life-threatening internal bleeding ...
(Date:7/13/2014)... Wa (PRWEB) July 13, 2014 According ... Vkool.com, this is a comprehensive program that teaches people ... peripheral neuropathy without medications. This program also ... relieving symptoms of peripheral neuropathy , including numbness, prickling, ... in its review that this home treatment program can ...
(Date:7/12/2014)... (PRWEB) July 13, 2014 Recently, iFitDress.com, one ... new selection of red evening gowns . What’s more, ... to 56% off. , The company’s senior spokesman states, “We ... shopping on our website is an enjoyable shopping experience. In ... In our online store, low prices do not always mean ...
Breaking Medicine News(10 mins):Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:Discounted Red Evening Gown Announced by iFitDress.com 2
... Stanford University School of Medicine and the Veterans Affairs Palo ... of low weight new- born deaths between 1991 and ... babies would have survived if they had been born in ... regional medical centers. This would afford the best chance of ...
... two state-run medical college hospitals in West Bengal entered its ... ,The house staff and interns of the Chittaranjan ... protesting a mob fury in which the hospital premises were ... Riyazuddin, died. ,A group of people from Riyazuddin's ...
... State University held a prayer and yoga session during the ... friendship and a lot of learning together," said Kanchan Banerjee, ... after the event Saturday. ,It has been 17 ... ,More than 30 students sat barefoot and cross-legged and chanted ...
... Any army is trained to kill. But the US military ... saving life. No it is not turning pacifist, certainly ... them provide the much needed critical medical care on the ... ,Officials said medical care given immediately after injuries ...
... breast cancer at the University of Cambridge claim to have ... ,They made this breakthrough by using the ... of DNA simultaneously instead of one by one. ... programme in 12 to 15 years, in which the inherited ...
... second most widespread neurodegenerative cause of dementia . ... disease. Getting the accurate diagnosis is particularly important ... health symptoms of Alzheimer's disease can be potentially ... ,The study found that even prior ...
Cached Medicine News:Health News:Low Weight Newborns at Greater Risk in Community Hospitals 2Health News:Low Weight Newborns at Greater Risk in Community Hospitals 3Health News:US Soldiers to Be Trained in Critical Medical Care 2Health News:Scientists Identify Four Genes That Raise the Risk of Breast Cancer 2Health News:Personality Changes may Help to Identify a Form of Dementia 2
Auto Suture MULTIFIRE PREMIUM skin stapler Disposable Loading Unit is a single use premium multi fire DLU that is available in four sizes....
... Appose Single Use Skin Staple Remover ... extractor design that is packaged 12 ... to remove skin staples. , ... lower jaws of the extractor under ...
... PROXIMATE RH skin stapler is a ... head assembly., ,PROXIMATE RH has improved ... along with a ratchet mechanism for easier ... a sterile, single patient use instrument designed ...
... use, reloadable articulating (22° and 45° in ... handle for resection, transection and anastomosis for ... stapler places two triple-staggered rows of staples ... in between. The instrument is designed for ...
Medicine Products: